Curis Dirección

Dirección controles de criterios 3/4

Curis' El consejero delegado es Jim Dentzer , nombrado en Sep 2018, tiene un mandato de 5.25 años. la remuneración anual total es $2.99M , compuesta por 20.5% salario y 79.5% primas, incluidas acciones y opciones de la empresa. posee directamente 0.093% de las acciones de la empresa, por valor de $57.72K . La antigüedad media del equipo directivo y del consejo de administración es de 4.3 años y 9.4 años respectivamente.

Información clave

Jim Dentzer

Chief Executive Officer (CEO)

US$3.0m

Compensación total

Porcentaje del salario del CEO	20.5%
Permanencia del CEO	5.6yrs
Participación del CEO	0.1%
Permanencia media de la dirección	4.7yrs
Promedio de permanencia en la Junta Directiva	9.7yrs

Actualizaciones recientes de la dirección

Recent updates

Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Apr 03

Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry

Dec 26

Curis stock soars 34% as FDA lifts partial clinical hold on emavusertib's lymphoma study

Aug 18

Curis: Asymmetric Risk And Reward

Jul 17

Here's Why We're Not Too Worried About Curis' (NASDAQ:CRIS) Cash Burn Situation

Mar 28

Checking In On Curis

Dec 15

Companies Like Curis (NASDAQ:CRIS) Can Afford To Invest In Growth

Dec 04

We Think Curis (NASDAQ:CRIS) Can Afford To Drive Business Growth

Aug 29

Curis Inc.: Revisiting CA-4948 After Q2 Update

Aug 25

Curis, Inc. (NASDAQ:CRIS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$16.33

Mar 19

Announcing: Curis (NASDAQ:CRIS) Stock Soared An Exciting 625% In The Last Year

Feb 17

Curis Inc.: Understanding CA-4948 And IRAK-4 Inhibition

Dec 23

Curis prices equity offering at $5.75/share

Dec 09

Curis skyrockets 141% on encouraging CA-4948 data in leukemia

Dec 08

What You Need To Know About Curis, Inc.'s (NASDAQ:CRIS) Investor Composition

Dec 03

Curis, National Cancer Institute in development pact for anti-cancer agent

Nov 11

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jim Dentzer en comparación con los beneficios de Curis?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$47m
Sep 30 2023	n/a	n/a	-US$47m
Jun 30 2023	n/a	n/a	-US$48m
Mar 31 2023	n/a	n/a	-US$52m
Dec 31 2022	US$3m	US$615k	-US$57m
Sep 30 2022	n/a	n/a	-US$59m
Jun 30 2022	n/a	n/a	-US$57m
Mar 31 2022	n/a	n/a	-US$52m
Dec 31 2021	US$3m	US$590k	-US$45m
Sep 30 2021	n/a	n/a	-US$39m
Jun 30 2021	n/a	n/a	-US$34m
Mar 31 2021	n/a	n/a	-US$30m
Dec 31 2020	US$2m	US$545k	-US$30m
Sep 30 2020	n/a	n/a	-US$31m
Jun 30 2020	n/a	n/a	-US$31m
Mar 31 2020	n/a	n/a	-US$32m
Dec 31 2019	US$2m	US$510k	-US$32m
Sep 30 2019	n/a	n/a	-US$29m
Jun 30 2019	n/a	n/a	-US$30m
Mar 31 2019	n/a	n/a	-US$32m
Dec 31 2018	US$2m	US$479k	-US$33m
Sep 30 2018	n/a	n/a	-US$35m
Jun 30 2018	n/a	n/a	-US$43m
Mar 31 2018	n/a	n/a	-US$48m
Dec 31 2017	US$2m	US$443k	-US$53m

Compensación vs. Mercado: Jim($USD2.99M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD738.70K).

Compensación vs. Ingresos: La compensación de Jim ha sido consistente con los resultados de la empresa en el último año.

CEO

Jim Dentzer (56 yo)

5.6yrs

Permanencia

US$2,994,100

Compensación

Mr. James E. Dentzer, also known as Jim, serves as Independent Director of Imunon, Inc. since September 2022. He serves as President, Chief Executive Officer & Director since September 24, 2018 and Secreta...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
James Dentzer	President	5.6yrs	US$2.99m	0.10% $ 96.7k
Diantha Duvall	CFO and Principal Financial & Accounting Officer	1.7yrs	US$1.09m	0.011% $ 10.2k
Mark Noel	Vice President of Technology Management & Intellectual Property	15.6yrs	US$413.39k	sin datos
Elif McDonald	VP of Investor Relations & Corporate Communications	no data	sin datos	sin datos
Reinhard von Roemeling	Senior Vice President of Clinical Development	4.7yrs	sin datos	sin datos
Jonathan Zung	Chief Development Officer	less than a year	sin datos	0% $ 0

4.7yrs

Permanencia media

56.5yo

Promedio de edad

Equipo directivo experimentado: CRISEl equipo directivo de la empresa se considera experimentado (4.3 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
James Dentzer	President	5.6yrs	US$2.99m	0.10% $ 96.7k
Martyn Greenacre	Independent Chairman of the Board	24.2yrs	US$326.45k	0.022% $ 20.7k
Marc Rubin	Independent Director	13.8yrs	US$297.32k	0.024% $ 22.9k
Kenneth Kaitin	Independent Director	20.4yrs	US$293.95k	0.024% $ 22.4k
John Hohneker	Independent Director	2.3yrs	US$279.82k	0% $ 0
Anne Borgman-Hagey	Independent Director	1.5yrs	US$74.60k	0% $ 0

9.7yrs

Permanencia media

65.5yo

Promedio de edad

Junta con experiencia: La junta directiva de CRIS se considera experimentada (9.4 años de antigüedad promedio).

Curis Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Curis, Inc., Annual General Meeting, May 21, 2024

Curis, Inc. Elects Anne E. Borgman as Class I Director

Curis, Inc. Announces Resignation of Lori A. Kunkel, M.D. from the Board of Directors, Effective September 30, 2022

Curis, Inc. Appoints Diantha Duvall as Chief Financial Officer, Treasurer, Assistant Secretary, Principal Financial Officer and Principal Accounting Officer of the Company Effective as of August 5, 2022

Curis, Inc. Announces Resignation of William Steinkrauss as Chief Administrative Officer, Effective from August 5, 2022

Curis, Inc., Annual General Meeting, May 26, 2022

Recent updates

Curis, Inc., Annual General Meeting, May 21, 2024

Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Consensus EPS estimates upgraded to US$6.06 loss

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 28%, EPS downgraded

Full year 2023 earnings: EPS and revenues miss analyst expectations

Curis, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Curis, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry

Curis, Inc. Announces Initial Combination Study Data from Its Take Aim Lymphoma Study

New major risk - Share price stability

Price target increased by 18% to US$180

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

We're A Little Worried About Curis' (NASDAQ:CRIS) Cash Burn Rate

Curis, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Share price stability

We're Hopeful That Curis (NASDAQ:CRIS) Will Use Its Cash Wisely

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Curis, Inc. to Report Q2, 2023 Results on Aug 03, 2023

U.S. Food and Drug Administration Removes Partial Clinical Hold on Curis, Inc.'s TakeAim Leukemia Study RP2D Established At 300 Mg BID

Consensus EPS estimates fall by 12%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?

Curis, Inc. Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS

Price target increased to US$15.33

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$12.25

Curis, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Curis Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price

Curis, Inc. Elects Anne E. Borgman as Class I Director

Curis, Inc. Announces Resignation of Lori A. Kunkel, M.D. from the Board of Directors, Effective September 30, 2022

Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Curis, Inc. Announces That the U.S. Food and Drug Administration (FDA) Has Notified Curis That It May Resume Enrollment of Additional Patients in the Monotherapy Phase of the TakeAim Leukemia Study

FDA Lifts Partial Clinical Hold on the Takeaim Lymphoma Study of Emavusertib of Curis, Inc

Curis stock soars 34% as FDA lifts partial clinical hold on emavusertib's lymphoma study

Price target increased to US$17.67

Curis, Inc. Appoints Diantha Duvall as Chief Financial Officer, Treasurer, Assistant Secretary, Principal Financial Officer and Principal Accounting Officer of the Company Effective as of August 5, 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Curis, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Curis: Asymmetric Risk And Reward

Curis, Inc. Announces Resignation of William Steinkrauss as Chief Administrative Officer, Effective from August 5, 2022

Curis, Inc.(NasdaqGM:CRIS) dropped from Russell 3000E Growth Index

Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)

Consensus EPS estimates fall by 14%

Price target increased to US$15.75

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$14.20

Curis, Inc., Annual General Meeting, May 26, 2022

Curis, Inc. Announces FDA Partial Clinical Hold for on the Company’s Takeaim Lymphoma Phase 1/2 Study

Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)

Here's Why We're Not Too Worried About Curis' (NASDAQ:CRIS) Cash Burn Situation

Curis, Inc. Announces Gastroenterology Publication of Encouraging Preclinical Data of Emavusertib in Pancreatic Cancers

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations

Curis, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory AML and MDS; and Initial Clinical Data from Phase 1 Study of CI-8993 in Patients with Relapsed or Refractory Solid Tumors

Checking In On Curis

Companies Like Curis (NASDAQ:CRIS) Can Afford To Invest In Growth

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.11 loss in 3Q 2020)

Insufficient new directors

Insufficient new directors

We Think Curis (NASDAQ:CRIS) Can Afford To Drive Business Growth

Curis Inc.: Revisiting CA-4948 After Q2 Update

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.17 loss in 2Q 2020)

Curis Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.28 loss in 1Q 2020)

Curis Receives U.S. Food and Drug Administration Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS